Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1979 Jul;37(1):98–105.

Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice.

S Kai, J Tanaka, K Nomoto, M Torisu
PMCID: PMC1537677  PMID: 314874

Abstract

The effects of the anti-tumour agent OK-432 on the immune response to hamster erythrocytes (HRBC) and nucleated chicken erythrocytes (CRBC) were studied in inbred SL mice. Mice were treated repeatedly with OK-432 before immunization with erythrocytes in saline. The cytotoxicity of CRBC-primed spleen cells, as demonstrated by 51Cr release from labelled CRBC, was markedly increased by treatment with OD-432. The delayed footpad reaction to CRBC was significantly augmented by treatment with OK-432. These results in mice indicate that OK-432 can enhance the cellular immune responses which require the contribution of T cells. Such an activation of T cells by OK-432 was observed in the humoral immune response to a trinitrophenyl group. Augmentation of anti-hapten antibody production, suggesting the enhancement of helper T cell activity by OK-432, was noticed after immunization with trinitrophenyl conjugated to erythrocytes. Furthermore, this enhancement of helper T cell activity by OK-432 was confirmed by utilizing an adoptive transfer system. These results support the possibility that T cell activation may be one of the important effects of OK-432 as an immunopotentiator.

Full text

PDF
99

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki T., Kvedar J. P., Hollis V. W., Jr, Bushar G. S. Streptococcus pyogenes preparation OK-432: immunoprophylactic and immunotherapeutic effects on the incidence of spontaneous leukemia in AKR mice. J Natl Cancer Inst. 1976 Mar;56(3):687–690. doi: 10.1093/jnci/56.3.687. [DOI] [PubMed] [Google Scholar]
  2. Askonas B. A., Roelants G. E. Macrophages bearing hapten-carrier molecules as foci inducers for T and B lymphocyte interaction. Eur J Immunol. 1974 Jan;4(1):1–4. doi: 10.1002/eji.1830040102. [DOI] [PubMed] [Google Scholar]
  3. Crowle A. J. Delayed hypersensitivity in the mouse. Adv Immunol. 1975;20:197–264. doi: 10.1016/s0065-2776(08)60209-6. [DOI] [PubMed] [Google Scholar]
  4. Doria G., Agarossi G., Boraschi D., Antonietta M. Effect of carrier priming on antibody avidity in the in vivo and in vitro immune response. Immunology. 1977 Apr;32(4):539–548. [PMC free article] [PubMed] [Google Scholar]
  5. Erb P., Feldmann M. Role of macrophages in in vitro induction of T-helper cells. Nature. 1975 Mar 27;254(5498):352–354. doi: 10.1038/254352a0. [DOI] [PubMed] [Google Scholar]
  6. Freedman L. R., Cerottini J. C., Brunner K. T. In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol. 1972 Dec;109(6):1371–1378. [PubMed] [Google Scholar]
  7. GRAY D. F., JENNINGS P. A. Allergy in experimental mouse tuberculosis. Am Rev Tuberc. 1955 Aug;72(2):171–195. doi: 10.1164/artpd.1955.72.2.171. [DOI] [PubMed] [Google Scholar]
  8. Grant C. K., Evans R., Alexander P. Multiple effector roles of lymphocytes in allograft immunity. Cell Immunol. 1973 Jul;8(1):136–146. doi: 10.1016/0008-8749(73)90100-7. [DOI] [PubMed] [Google Scholar]
  9. Ishii Y., Yamaoka H., Toh K., Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gan. 1976 Feb;67(1):115–119. [PubMed] [Google Scholar]
  10. Kaibara N., Ikeda T., Hattori T., Inokuchi K. Effectiveness of treatment using a streptococcal preparation (PC-B-45) and mitomycin-C on transplanted mouse tumor. Gan. 1972 Jun;63(3):387–390. [PubMed] [Google Scholar]
  11. Katz D. H., Benacerraf B. The regulatory influence of activated T cells on B cell responses to antigen. Adv Immunol. 1972;15:1–94. doi: 10.1016/s0065-2776(08)60683-5. [DOI] [PubMed] [Google Scholar]
  12. Kettman J., Dutton R. W. Radioresistance of the enhancing effect of cells from carrier-immunized mice in an in vitro primary immune response. Proc Natl Acad Sci U S A. 1971 Apr;68(4):699–703. doi: 10.1073/pnas.68.4.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kimura I., Onoshi T., Yasuhara S., Watanabe T., Sugiyama M., Hiraki K. Studies on the host-mediated action of the streptococcal preparation, OK-432, in cancer chemotherapy. Acta Med Okayama. 1974 Dec;28(6):423–431. [PubMed] [Google Scholar]
  14. Kitamura Y., Nomoto K., Torisu M., Takeya K. Effects of BCG (Bacillus Calmette-Guérin) vaccines on immune responses in mice. I. Possible effect of BCG on helper T cells. Jpn J Microbiol. 1976 Aug;20(4):303–308. doi: 10.1111/j.1348-0421.1976.tb00992.x. [DOI] [PubMed] [Google Scholar]
  15. Kondo M., Ikezaki M., Imanishi H., Nishigaki I., Hosokawa K. Streptococcal preparation as an activator of host-mediated immune response: cellular immunity and alternate pathway of complement. Gan. 1975 Dec;66(6):675–678. [PubMed] [Google Scholar]
  16. Kubo C., Nomoto K., Sato M., Takeya K. Direct cytotoxicity against chicken erythrocytes in mice. I. Fundamental nature of T cell-mediated cytotoxicity. Immunology. 1977 Dec;33(6):895–905. [PMC free article] [PubMed] [Google Scholar]
  17. Miller T. E., Mackaness G. B., Lagrange P. H. Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells. J Natl Cancer Inst. 1973 Nov;51(5):1669–1676. doi: 10.1093/jnci/51.5.1669. [DOI] [PubMed] [Google Scholar]
  18. Ohmichi Y., Nomoto K., Yamada H., Takeya K. Relationships among differentiated T-cell subpopulations. I. Dissociated development of tuberculin type hypersensitivity, Jones-Mote type hypersensitivity and activation of helper function. Immunology. 1976 Jul;31(1):101–110. [PMC free article] [PubMed] [Google Scholar]
  19. Okamoto H., Shoin S., Koshimura S., Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol. 1967 Dec;11(4):323–326. doi: 10.1111/j.1348-0421.1967.tb00350.x. [DOI] [PubMed] [Google Scholar]
  20. Ono T., Kurata S., Wakabayashi K., Sugawara Y., Saito M. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gan. 1973 Feb;64(1):59–64. [PubMed] [Google Scholar]
  21. Perlmann P., Perlmann H. Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes. Cell Immunol. 1970 Sep;1(3):300–315. doi: 10.1016/0008-8749(70)90051-1. [DOI] [PubMed] [Google Scholar]
  22. Pritchard H., Micklem H. S. Immune responses in congenitally thymus-less mice. I. Absence of response to oxazolone. Clin Exp Immunol. 1972 Jan;10(1):151–161. [PMC free article] [PubMed] [Google Scholar]
  23. Rajewsky K., Schirrmacher V., Nase S., Jerne N. K. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med. 1969 Jun 1;129(6):1131–1143. doi: 10.1084/jem.129.6.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rittenberg M. B., Amkraut A. A. Immunogenicity of trinitrophenyl-hemocyanin: production of primary and secondary anti-hapten precipitins. J Immunol. 1966 Sep;97(3):421–430. [PubMed] [Google Scholar]
  25. Rittenberg M. B., Pratt K. L. Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen. Proc Soc Exp Biol Med. 1969 Nov;132(2):575–581. doi: 10.3181/00379727-132-34264. [DOI] [PubMed] [Google Scholar]
  26. Sakai S., Ryoyama K., Koshimura S., Migita S. Studies on the properties of a streptococcal preparation OK-432 (NSC-B116209) as an immunopotentiator. I. Activation of serum complement components and peritoneal exudate cells by group A streptococcus. Jpn J Exp Med. 1976 Apr;46(2):123–133. [PubMed] [Google Scholar]
  27. Suzuki S., Yamamoto A., Ogawa H. Inhibitory effect of a streptococcal preparation (OK-432) on induction of splenomegaly by Friend leukemia virus. Gan. 1975 Aug;66(4):455–456. [PubMed] [Google Scholar]
  28. Torisu M., Fukawa M., Nishimura M., Harasaki H., Kai S., Tanaka J. Immunotherapy of cancer patients with Bacillus Calmette-Guérin: summary of four years of experience in Japan. Ann N Y Acad Sci. 1976;277(00):160–186. doi: 10.1111/j.1749-6632.1976.tb41696.x. [DOI] [PubMed] [Google Scholar]
  29. Tsukagoshi S., Sakurai Y., Sato H., Akiba T SUZUKI S. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep. 1972 Feb;56(1):9–17. [PubMed] [Google Scholar]
  30. Unanue E. R., Katz D. H. Immunogenicity of macrophage-bound antigens: the requirement for hapten and carrier determinants to be on the same molecule for T and B lymphocyte collaboration. Eur J Immunol. 1973 Sep;3(9):559–563. doi: 10.1002/eji.1830030907. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES